Clinical trials: Recurrent CNS Tumors
Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous…
- Trial name
- NCT07297212
- Testing
- Pumitamig, Bevacizumab, Temozolomide
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Glioblastoma Multiforme, Brain Tumor
Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients
This study is to evaluate the safety and find the tolerated ultrasound dose of transient opening of the blood-brain barrier (BBB) by using the NaviFUS System in recurrent GBM patients.
- Conditions
- Glioblastoma Multiforme, Brain Tumor, Glioblastoma, Glioma
- Trial name
- NCT03626896
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Recurrent Glioblastoma Multiforme
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A.
- Trial name
- NCT00379470
- Testing
- NovoTTF-100A
- Where
- 25 sites in United States, Austria and 5 more
- Volunteers
- 236 people
- Sponsor
- NovoCure Ltd.
Brain and Central Nervous System Tumors
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic…
- Trial name
- NCT00003775
- Testing
- leflunomide
- Where
- 26 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Pfizer
Cancer, Pediatric Cancer
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
- Trial name
- NCT07773454
- Testing
- Zanzalintinib
- Volunteers
- 18 people
- Sponsor
- Exelixis
Breast Neoplasm, Brain Neoplasm
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
- Conditions
- Breast Neoplasm, Brain Neoplasm, Second Neoplasm
- Trial name
- STOP (NCT00638963)
- Testing
- temozolomide
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastasis, Non-small Cell Lung Cancer
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after…
- Trial name
- NCT00219297
- Testing
- Patupilone
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Glioma, Glioblastoma Multiforme
Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00591058
- Testing
- TM-601
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- TransMolecular
Astrocytoma, Glioblastoma
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects…
- Trial name
- NCT04047303
- Testing
- CC-90010
- Where
- 4 sites in United States, Spain
- Volunteers
- 20 people
- Sponsor
- Celgene
Central Nervous System Neoplasms, Medulloblastoma
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to < 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types…
- Trial name
- NCT03257631
- Testing
- Pomalidomide
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 53 people
- Sponsor
- Celgene
Glioblastoma Multiforme, Glioblastoma
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT06329570
- Testing
- NaviFUS System, Lumason, Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NaviFUS Corporation
Central Nervous System Neoplasms, Glioblastoma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting…
- Conditions
- Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma
- Trial name
- NCT04541082
- Testing
- ONC206
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jazz Pharmaceuticals
Glioblastoma, Small Cell Glioblastoma
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ReACT (NCT01498328)
- Testing
- Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
- Where
- 45 sites in United States
- Volunteers
- 127 people
- Sponsor
- Celldex Therapeutics
Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor…
- Conditions
- Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM)
- Trial name
- NCT07751744
- Testing
- JBI-778
- Volunteers
- 113 people
- Sponsor
- Jubilant Therapeutics Inc.
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Brain Neoplasms, Brain Tumor
MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors
The purpose of this study is to determine if the stereotactic, MR guided, laser interstitial thermal therapy treatment technique can be safety and efficiently used for human brain metastasis and primary brain tumors.
- Conditions
- Brain Neoplasms, Brain Tumor, Brain Cancer, Recurrent Brain Tumor
- Trial name
- NCT00392119
- Testing
- MR-guided Laser Interstitial Thermal Therapy System
- Where
- France
- Volunteers
- 18 people
- Sponsor
- BioTex, Inc.
Recurrent Glioblastoma
An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
The purpose of this study is to test Y90 glass microspheres for people with recurrent brain cancer. Participation in this study will help researchers find the best dose for the treatment of the disease.
- Trial name
- ODYSSEY (NCT07867886)
- Testing
- Device: TheraSphere GBM treatment of TheraSphere GBM device
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
This is a multicenter study evaluating the safety and tolerability of Toca 511 administered intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who have elected to undergo surgical removal of…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01985256
- Testing
- Toca 511, Toca FC
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Tocagen Inc.